MGluR4-positive allosteric modulation as potential treatment for Parkinson's disease

Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Although Parkinsons disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-L-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinsons disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson's disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinsons disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinsons disease.

Original languageEnglish (US)
Pages (from-to)501-513
Number of pages13
JournalFuture Medicinal Chemistry
Volume1
Issue number3
DOIs
StatePublished - Jun 1 2009

Fingerprint

Parkinson Disease
Therapeutics
Nerve Degeneration
Metabotropic Glutamate Receptors
Dopaminergic Neurons
metabotropic glutamate receptor 4
Phenylalanine
Glutamic Acid
Rodentia
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

MGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. / Hopkins, Corey R.; Lindsley, Craig W.; Niswender, Colleen M.

In: Future Medicinal Chemistry, Vol. 1, No. 3, 01.06.2009, p. 501-513.

Research output: Contribution to journalReview article

Hopkins, Corey R. ; Lindsley, Craig W. ; Niswender, Colleen M. / MGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. In: Future Medicinal Chemistry. 2009 ; Vol. 1, No. 3. pp. 501-513.
@article{222d324e28a944c6a76de0e962ae974b,
title = "MGluR4-positive allosteric modulation as potential treatment for Parkinson's disease",
abstract = "Although Parkinsons disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-L-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinsons disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson's disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinsons disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinsons disease.",
author = "Hopkins, {Corey R.} and Lindsley, {Craig W.} and Niswender, {Colleen M.}",
year = "2009",
month = "6",
day = "1",
doi = "10.4155/fmc.09.38",
language = "English (US)",
volume = "1",
pages = "501--513",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "3",

}

TY - JOUR

T1 - MGluR4-positive allosteric modulation as potential treatment for Parkinson's disease

AU - Hopkins, Corey R.

AU - Lindsley, Craig W.

AU - Niswender, Colleen M.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Although Parkinsons disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-L-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinsons disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson's disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinsons disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinsons disease.

AB - Although Parkinsons disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-L-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinsons disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson's disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinsons disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinsons disease.

UR - http://www.scopus.com/inward/record.url?scp=68349137048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349137048&partnerID=8YFLogxK

U2 - 10.4155/fmc.09.38

DO - 10.4155/fmc.09.38

M3 - Review article

C2 - 20161443

AN - SCOPUS:68349137048

VL - 1

SP - 501

EP - 513

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 3

ER -